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Abstract
Endothelial dysfunction is associated with major causes of morbidity and mortality, as well as
numerous age-related conditions. The possibility of preserving or even rejuvenating endothelial
function offers a potent means of preventing/treating some of the most fearful aspects of aging such
as loss of mental, cardiovascular, and sexual function.
Endothelial precursor cells (EPC) provide a continual source of replenishment for damaged or
senescent blood vessels. In this review we discuss the biological relevance of circulating EPC in a
variety of pathologies in order to build the case that these cells act as an endogenous mechanism
of regeneration. Factors controlling EPC mobilization, migration, and function, as well as
therapeutic interventions based on mobilization of EPC will be reviewed. We conclude by
discussing several clinically-relevant approaches to EPC mobilization and provide preliminary data
on a food supplement, Stem-Kine, which enhanced EPC mobilization in human subjects.
Introduction
The endothelium plays several functions essential for life,
including: a) acting as an anticoagulated barrier between
the blood stream and interior of the blood vessels; b)
allowing for selective transmigration of cells into and out
of the blood stream; c) regulating blood flow through
controlling smooth muscle contraction/relaxation; and d)
participating in tissue remodeling [1]. A key hallmark of
the aging process and perhaps one of the causative factors
of health decline associated with aging appears to be loss
of endothelial function. Whether as a result of oxidative
stress, inflammatory stress, or senescence, deficiencies in
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the ability of the endothelium to respond to physiological
cues can alter mental [2], sexual [3], visual [4], and respi-
ratory [5] ability. Specifically, minute alterations in the
ability of endothelium to respond to neurotransmitter
induced nitric oxide causes profound inability to perform
even simple mental functions [6,7]. Small increases in
angiogenesis in the retina as a result of injury or glucose
are associated with wet macular degeneration blindness
[8]. Atherosclerosis of the penile vasculature is a major
cause of erectile dysfunction [9]. The pulmonary endothe-
lium's sensitivity to insult can cause hypertension and
associated progression to decreased oxygen delivery [10].
Health of the endothelium can be quantified using several
methods, including assessment of the physical and
mechanical features of the vessel wall, assaying for pro-
duction of systemic biomarkers released by the endothe-
lium, and quantification of ability of blood vessels to
dilate in response to increased flow [11]. Of these, one of
the most commonly used assays for endothelium func-
tion is the flow mediated dilation (FMD) assay. This pro-
cedure usually involves high resolution ultrasound
assessment of the diameter of the superficial femoral and
brachial arteries in response to reactive hyperemia
induced by a cuff. The extent of dilatation response
induced by the restoration of flow is compared to dilata-
tion induced by sublingual glyceryl trinitrate. Since the
dilatation induced by flow is dependent on the endothe-
lium acting as a mechanotransducer and the dilatation
induced by glyceryl trinitrate is based on smooth muscle
responses, the difference in dilatation response serves as a
means of quantifying one aspect of endothelial health
[12,13]. This assay has been used to show endothelial dys-
function in conditions such as healthy aging [14-16], as
well as various diverse inflammatory states including
renal failure [17], rheumatoid arthritis [18], Crohn's Dis-
ease [19], diabetes [20], heart failure [21], and Alzhe-
imer's [22]. Although it is not clear whether reduction in
FMD score is causative or an effect of other properties of
endothelial dysfunction, it has been associated with: a)
increased tendency towards thrombosis, in part by
increased von Willibrand Factor (vWF) levels [23], b)
abnormal responses to injury, such as neointimal prolifer-
ation and subsequent atherosclerosis [24], and c)
increased proclivity towards inflammation by basal
upregulation of leukocyte adhesion molecules [25].
As part of age and disease associated endothelial dysfunc-
tion is the reduced ability of the host to generate new
blood vessel [26]. This is believed to be due, at least in
part, to reduction of ischemia inducible elements such as
the HIF-1 alpha transcription factor which through induc-
tion of stromal derived factor (SDF-1) and vascular
endothelial growth factor (VEGF) secretion play a critical
role in ability of endothelium to migrate and form new
capillaries in ischemic tissues [27,28]. Accordingly, if one
were to understand the causes of endothelial dysfunction
and develop methods of inhibiting these causes or stimu-
lating regeneration of the endothelium, then progression
of many diseases, as well as possible increase in healthy
longevity may be achieved.
Endothelial Progenitor Cells: Rejuvenators of the 
Vasculature
During development endothelial cells are believed to orig-
inate from a precursor cell, the hemangioblast, which is
capable of giving rise to both hematopoietic and endothe-
lial cells [29]. Classically the endothelium was viewed as
a fixed structure with relatively little self renewal, however
in the last two decades this concept has fundamentally
been altered. The current hypothesis is that the endothe-
lium is constantly undergoing self renewal, especially in
response to stress. A key component of endothelial turno-
ver appears to be the existence of circulating endothelial
progenitor (EPC) cells that appear to be involved in repair
and angiogenesis of ischemic tissues. An early study in
1963 hinted at the existence of such circulating EPC after
observations of endothelial-like cells, that were non-
thrombogenic and morphologically appeared similar to
endothelium, were observed covering a Dacron graft that
was tethered to the thoracic artery of a pig [30]. The
molecular characterization of the EPC is usually credited
to a 1997 paper by Asahara et al. in which human bone
marrow derived VEGR-2 positive, CD34 positive mono-
cyte-like cells were described as having ability to differen-
tiate into endothelial cells in vitro and in vivo based on
expression of CD31, eNOS, and E-selectin [31]. These
studies were expanded into hindlimb ischemia in mouse
and rabbit models in which increased circulation of EPC
in response to ischemic insult was observed [32]. Further-
more, these studies demonstrated that cytokine-induced
augmentation of EPC mobilization elicited a therapeutic
angiogenic response. Using irradiated chimeric systems, it
was demonstrated that ischemia-mobilized EPC derive
from the bone marrow, and that these cells participate
both in sprouting of pre-existing blood vessels as well as
the initiation of de novo blood vessel production [33].
Subsequent to the initial phenotypic characterization by
Asahara et al [31], more detailed descriptions of the
human EPC were reported. For example, CD34 cells
expressing the markers VEGF-receptor 2, CD133, and
CXCR-4 receptor, with migrational ability to VEGF and
SDF-1 has been a more refined EPC definition [34]. How-
ever there is still some controversy as to the precise pheno-
type of the EPC, since the term implies only ability to
differentiate into endothelium. For example, both
CD34+, VEGFR2+, CD133+, as well as CD34+, VEGFR2+,
CD133- have been reported to act as EPC [35]. More
recent studies suggest that the subpopulation lacking
CD133 and CD45 are precursor EPC [36]. Other pheno-Journal of Translational Medicine 2009, 7:106 http://www.translational-medicine.com/content/7/1/106
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types have been ascribed to cells with EPC activity, one
study demonstrated monocyte-like cells that expressing
CD14, Mac-1 and the dendritic cell marker CD11c have
EPC activity based on uptake of acetylated LDL and bind-
ing to the ulex-lectin [37,38].
While the initial investigations into the biology of EPC
focused around acute ischemia, it appears that in chronic
conditions circulating EPC may play a role in endothelial
turnover. Apolipoprotein E knockout (ApoE KO) mice are
genetically predisposed to development of atherosclerosis
due to inability to impaired catabolism of triglyceride-rich
lipoproteins. When these mice are lethally irradiated and
reconstituted with labeled bone marrow stem cells, it was
found that areas of the vasculature with high endothelial
turnover, which were the areas of elevated levels of sheer
stress, had incorporated the majority of new endothelial
cells derived from the bone marrow EPC [39]. The possi-
bility that endogenous bone marrow derived EPC possess
such a regenerative function was also tested in a therapeu-
tic setting. Atherosclerosis is believed to initiate from
endothelial injury with a proliferative neointimal
response that leads to formation of plaques. When bone
marrow derived EPC are administered subsequent to wire
injury, a substantial reduction in neointima formation
was observed [40]. The argument can obviously made that
wire injury of an artery does not resemble the physiologi-
cal conditions associated with plaque development. To
address this, Wassmann et al [41], used ApoE KO mice
that were fed a high cholesterol diet and observed reduc-
tion in endothelial function as assessed by the flow medi-
ated dilation assay. When EPC were administered from
wild-type mice restoration of endothelial responsiveness
was observed.
In the context of aging, Edelman's group performed a
series of interesting experiments in which 3 month old
syngeneic cardiac grafts were heterotopically implanted
into 18 month old recipients. Loss of graft viability, asso-
ciated with poor neovascularization, was observed subse-
quent to transplanting, as well as subsequent to
administration of 18 month old bone marrow mononu-
clear cells. In contrast, when 3 month old bone marrow
mononuclear cells were implanted, grafts survived. Anti-
body depletion experiments demonstrated bone marrow
derived platelet derived growth factor (PDGF)-BB was
essential in integration of the young heart cells with the
old recipient vasculature [42]. These experiments suggest
that young EPC or EPC-like cells have ability to integrate
and interact with older vasculature. What would be inter-
esting is to determine whether EPC could be "revitalized"
ex vivo by culture conditions or transfection with thera-
peutic genes such as PDGF-BB.
Given animal studies suggest EPC are capable of replen-
ishing the vasculature, and defined markers of human
EPC exist, it may be possible to contemplate EPC-based
therapies. Two overarching therapeutic approaches would
involve utilization of exogenous EPC or mobilization of
endogenous cells. Before discussing potential therapeutic
interventions, we will first examine several clinical condi-
tions in which increasing circulating EPC may play a role
in response to injury.
Clinical Increase of Circulating EPC as a Response to 
Injury
Tissue injury and hypoxia are known to generate chem-
oattractants that potentially are responsible for mobiliza-
tion of EPC. Reduction in oxygen tension occurs as a
result of numerous injuries including stroke, infarction, or
contusion. Oxygen tension is biologically detected by the
transcription factor HIF-1 alpha, which upon derepres-
sion undergoes nuclear translocation. This event causes
upregulated expression of a plethora of angiogenesis pro-
moting cytokines and chemoattractants [43], such as stro-
mal derived factor (SDF)-1 and VEGF [44,45]. On the
other hand, tissue necrosis causes release of "danger sig-
nals" such as HMBG1, a nuclear factor that has direct che-
moattractant activity on mesoangioblasts, a type of EPC
[46,47]. It has been demonstrated that this systemic
release of chemoattractant cytokines after vascular injury
or infarct is associated with mobilization of endogenous
bone marrow cells and EPC [48].
Myocardial infarction has been widely studied in the area
of regenerative medicine in which cellular and molecular
aspects of host response post-injury are relatively well
defined. EPC mobilization after acute ischemia has been
demonstrated in several cardiac infarct studies. This was
first reported by Shintani et al who observed increased
numbers of CD34 positive cells in 16 post infarct patients
on day 7 as compared to controls. The rise in CD34 cells
correlated with ability to differentiate into cells morpho-
logically resembling endothelium and expressing
endothelial markers KDR and CD31. Supporting the con-
cept that response to injury stimulates EPC mobilization,
a rise in systemic VEGF levels was correlated with
increased EPC numbers [45]. A subsequent study demon-
strated a similar rise in circulating EPC post infarct. Blood
was drawn from 56 patients having a recent infarct (<12
hours), 39 patients with stable angina, and 20 healthy
controls. Elevated levels of cells expressing CD34/
CXCR4+ and CD34/CD117+ and c-met+ were observed
only in the infarct patients which were highest at the first
blood draw. In this study the mobilized cells not only
expressed endothelial markers, but also myocytic and car-
diac genes [49]. The increase in circulating EPC at early
timepoints post infarction has been observed by otherJournal of Translational Medicine 2009, 7:106 http://www.translational-medicine.com/content/7/1/106
Page 4 of 12
(page number not for citation purposes)
groups, and correlated with elevations in systemic VEGF
and SDF-1 [50,51].
In the case of cerebral infarction studies support the con-
cept that not only are EPC mobilized in response to
ischemia, but also that the extent of mobilization may be
associated with recovery. In a trial of 48 patients suffering
primary ischemic stroke, mobilization of EPC was
observed in the first week in comparison to control
patients. EPC were defined as cells capable of producing
endothelial colony forming units. A correlation between
improved outcome at 3 months and extend of EPC mobi-
lization was observed based on the NIHSS and Rankin
score [52]. In a similar study, Dunac et al reported on cir-
culating CD34 levels of 25 patients with acute stroke for
14 days. A correlation between improvement on the
Rankin scale and increased circulating CD34 cells was
reported [53]. Noteworthy was that the level of CD34
mobilization was similar to that observed in patients
treated with the mobilize G-CSF. In a larger study, Yip et
al examined EPC levels in 138 consecutive patients with
acute stroke and compared them to 20 healthy volunteers
and in 40 at-risk control subjects [54]. Three EPC pheno-
types were assessed by flow cytometry at 48 hours after
stroke: a) CD31/CD34, b) CD62E/CD34, and c) KDR/
CD34. Diminished levels of all three EPC subsets in circu-
lation was predictive of severe neurological impairment
NIHSS >/= 12, while suppressed levels of circulating
CD31/34 cells was correlated with combined major
adverse clinical outcomes as defined by recurrent stroke,
any cause of death, or NIHSS >/= 12. Increased levels of
the KDR/CD34 phenotype cells was strongly associated
with NIHSS > or = 4 on day 21. Although these studies do
not directly demonstrate a therapeutic effect of the mobi-
lized EPC, animal studies in the middle cerebral artery
ligation stroke model have demonstrated positive effects
subsequent to EPC administration [55,56], an effect
which appears to be at least partially dependent on VEGF
production from the EPC [57].
Another ischemia-associated tissue insult is acute respira-
tory distress syndrome (ARDS), in which respiratory fail-
ure often occurs as a result of disruption of the alveolar-
capillary membrane, which causes accumulation of pro-
teinaceous pulmonary edema fluid and lack of oxygen
uptake ability [58]. In this condition there has been some
speculation that circulating EPC may be capable of restor-
ing injured lung endothelium. For example, it is known
that significant chimerism (37-42%) of pulmonary
endothelial cells occurs in female recipients of male bone
marrow transplants [59]. Furthermore, in patients with
pneumonia infection there is a correlation between infec-
tion and circulating EPC, with higher numbers of EPC
being indicative of reduced fibrosis [60]. The possibility
that EPC are mobilized during ARDS and may be associ-
ated with benefit was examined in a study of 45 patients
with acute lung injury in which a correlation between
patients having higher number of cells capable of forming
endothelial colonies in vitro and survival was made. Spe-
cifically, the patients with a colony count of >or= 35 had
a mortality of approximately 30%, compared to patients
with less than 35 colonies, which had a mortality of 61%.
The correlation was significant after multivariable analysis
correcting for age, sex, and severity of illness [61]. From an
interventional perspective, transplantation of EPC into a
rabbit model of acute lung injury resulted in reduction of
leukocytic infiltrates and preservation of pulmonary cellu-
lar integrity [62].
Sepsis is a major cause of ARDS and is associated with
acute systemic inflammation and vascular damage. Septic
patients have elevated levels of injury associated signals
and EPC mobilizers such as HMGB1 [63], SDF-1 [64], and
VEGF [65]. Significant pathology of sepsis is associated
with vascular leak and disseminated intravascular coagu-
lation [66]. The importance of the vasculature in sepsis
can perhaps be supported by the finding that the only
drug to have an impact on survival, Activated Protein C,
acts primarily through endothelial protection [67]. Septic
patients are known to have increased circulating EPC as
compared to controls. Becchi et al observed a correlation
between VEGF and SDF-1 levels with a 4-fold rise in circu-
lating EPC in septic patients as compared to healthy con-
trols [64]. A correlation between EPC levels and survival
after sepsis was reported in a study of 32 septic patients,
15 ICU patients, and 15 controls. Of the 8 patients who
succumbed to sepsis by 28 days, as compared to 24 survi-
vors, a significantly reduced EPC number in non-survivors
was reported [68].
It appears that in conditions of acute injury, elevation of
EPC in circulation occurs. Although studies in stroke [52-
54], ARDS [61], and sepsis [68] seem to correlate outcome
with extend of mobilization, work remains to be per-
formed in assessing whether it is the EPC component that
is responsible for benefits or other confounding variables.
Taking into account the possibility that EPC may act as an
endogenous repair mechanism, we will discuss data in
chronic degenerative conditions in which circulating EPC
appear to be suppressed.
Chronic Inflammatory Disease Inhibit Circulating EPC
There is need for angiogenesis and tissue remodeling in
the context of various chronic inflammatory conditions.
However in many situations it is the aberrant reparative
processes that actually contribute to the pathology of dis-
ease. Examples of this include: the process of neointimal
hyperplasia and subsequent plaque formation in response
to injury to the vascular wall [69], the process of hepatic
fibrosis as opposed to functional regeneration [70], or theJournal of Translational Medicine 2009, 7:106 http://www.translational-medicine.com/content/7/1/106
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post-infarct pathological remodeling of the myocardium
which results in progressive heart failure [71]. In all of
these situations it appears that not only the lack of regen-
erative cells, but also the lack of EPC is present. Conceptu-
ally, the need for reparative cells to heal the ongoing
damage may have been so overwhelming that it leads to
exhaustion of EPC numbers and eventual reduction in
protective effect. Supporting this concept are observations
of lower number of circulating EPC in inflammatory dis-
eases, which may be the result of exhaustion. Addition-
ally, the reduced telomeric length of EPC in patients with
coronary artery disease [72], as well as reduction of tel-
omere length in the EPC precursors that are found in the
bone marrow [73,74] suggests that exhaustion in
response to long-term demand may be occurring. If the
reparatory demands of the injury indeed lead to depletion
of EPC progenitors, then administration of progenitors
should have therapeutic effects.
Several experiments have shown that administration of
EPC have beneficial effects in the disease process. For
example, EPC administration has been shown to: decrease
balloon injury induced neointimal hyperplasia [75], b)
suppress carbon tetrachloride induced hepatic fibrosis
[76,77], and inhibit post cardiac infarct remodeling [78].
One caveat of these studies is that definition of EPC was
variable, or in some cases a confounding effect of coad-
ministered cells with regenerative potential may be
present. However, overall, there does appear to be an indi-
cation that EPC play a beneficial role in supporting tissue
regeneration. As discussed below, many degenerative con-
ditions, including healthy aging, are associated with a
low-grade inflammation. There appears to be a causative
link between this inflammation and reduction in EPC
function.
Inflammatory conditions present with features, which
although not the rule, appear to have commonalities. For
example, increases in inflammatory markers such as C-
reactive protein (CRP), erythrocyte sedimentation rate,
and cytokines such as TNF-alpha and IL-18 have been
described in diverse conditions ranging from organ
degenerative conditions such as heart failure [79,80], kid-
ney failure [81,82], and liver failure [83,84] to autoim-
mune conditions such as rheumatoid arthritis [85] and
Crohn's Disease [86], to healthy aging [87,88]. Other
markers of inflammation include products of immune
cells such as neopterin, a metabolite that increases system-
ically with healthy aging [89], and its concentration posi-
tively correlates with cognitive deterioration in various
age-related conditions such as Alzheimer's [90]. Neop-
terin is largely secreted by macrophages, which also pro-
duce inflammatory mediators such as TNF-alpha, IL-1,
and IL-6, all of which are associated with chronic inflam-
mation of aging [91]. Interestingly, these cytokines are
known to upregulate CRP, which also is associated with
aging [92]. While there is no direct evidence that inflam-
matory markers actively cause shorted lifespan in
humans, strong indirect evidence of their detrimental
activities exists. For example, direct injection of recom-
binant CRP in healthy volunteers induces atherothrom-
botic endothelial changes, similar to those observed in
aging [93]. In vitro administration of CRP to endothelial
cells decreases responsiveness to vasoactive factors, resem-
bling the human age-associated condition of endothelial
hyporesponsiveness [94].
Another important inflammatory mediator found ele-
vated in numerous degenerative conditions is the cytokine
TNF-alpha. Made by numerous cells, but primarily macro-
phages, TNF-alpha is known to inhibit proliferation of
repair cells in the body, such as oligodendrocytes in the
brain [95], and suppress activity of endogenous stem cell
pools [96,97]. TNF-alpha decreases EPC viability, an effect
that can be overcome, at least in part by antioxidant treat-
ment [98]. Administration of TNF-alpha blocking agents
has been demonstrated to restore both circulating EPC, as
well as endothelial function in patients with inflamma-
tory diseases such as rheumatoid arthritis [18,99,100],
It appears that numerous degenerative conditions are
associated with production of inflammatory mediators,
which directly suppress EPC production or activity. This
may be one of the reasons for findings of reduced EPC and
FMD indices in patients with diverse inflammatory condi-
tions. In addition to the direct effects, the increased
demand for de novo EPC production in inflammatory
conditions would theoretically lead to exhaustion of EPC
precursors cells by virtue of telomere shortening.
EPC Exhaustion as a Mechanism of Chronic Inflammation
On average somatic cells can divide approximately 50
times, after which they undergo senescence, die or
become cancerous. This limited proliferative ability is
dependent on the telomere shortening problem. Every
time cells divide the ends of the chromosomes called "tel-
omeres" (complexes of tandem TTAGGGG repeats of
DNA and proteins), are not completely replicated, thus
they progressively get shorter [101]. Once telomeres reach
a critical limit p53, p21, and p16 pathways are activated
as a DNA damage response reaction instructing the cell to
exit cell cycling. Associated with the process of senescence,
the cells start expressing inflammatory cytokines such as
IL-1 [102,103], upregulation of adhesion molecules that
attract inflammatory cells such as monocytes [104,105],
and morphologically take a flattened, elongated appear-
ance. Physiologically, the process of cellular senescence
caused in response to telomere shortening is believed to
be a type of protective mechanism that cells have to pre-
vented carcinogenesis [106]. At a whole organism level
the association between telomere length and age has been
made [107], as well, disorders of premature aging such asJournal of Translational Medicine 2009, 7:106 http://www.translational-medicine.com/content/7/1/106
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ataxia telangiectasia are characterized by accelerated tel-
omere shortening [108].
The importance of this limited proliferative ability
becomes apparent in our discussion of EPC. In general
there is a need for continual endothelial cell replacement
from EPC. Because the endothelial cells are exposed to
enormous continual sheer stress of blood flow, mecha-
nisms of repair and proliferation after injury need to exist.
Theoretically, the more sheer stress on a particular artery,
the more cell division would be required to compensate
for cell loss. Indeed this appears to be the case. For exam-
ple, telomeres are shorter in arteries associated with
higher blood flow and sheer stress (like the iliac artery) as
compared to arteries of lower stress such as the mammary
artery [109]. The theory that senescence may be associated
with atherosclerosis is supported since the iliac artery,
which is associated with higher proliferation of endothe-
lial cells and is also at a higher risk of atherosclerosis, thus
prompting some investigators to propose atherosclerosis
being associated with endothelial senescence [110,111].
In an interesting intervention study Satoh et al examined
100 patients with coronary artery disease and 25 control
patients. Telomere lengths were reduced in EPC of coro-
nary artery disease patients as compared to controls. Lipid
lowering therapy using agents such as atorvastatin has
previously been shown to reduced oxidative stress and
increase circulating EPC. Therapy with lipid lowering
agents in this study resulted in preservation of telomeric
length, presumably by decreasing the amount of de novo
EPC produced, as well as oxidative stress leading to tel-
omere erosion [112]. One important consideration when
discussing telomere shortening of EPC is the difference
between replicative senescence, which results from high
need for differentiated endothelial cells, and stress
induced senescence, in which inflammatory mediators
can directly lead to telomere shortening. For example,
smoking associated oxidative stress has been linked to
stress induced senescence in clinical studies [113],
whereas other studies have implicated inflammatory
agents such as interferon gamma [114], TNF-alpha [115],
and oxidative mediators as inducers of stress induced
senescence [116].
Intervening to Increase Vascular Health and EPC
Based on the above descriptions, it appears that in degen-
erative conditions, as well as in aging, an underlying
inflammatory response occurs that is directly or indirectly
associated with inhibition of circulating EPC activity.
Directly, inflammation is known to suppress stem cell
turnover and activity of EPC. Indirectly, inflammatory
conditions place increased demands on the EPC progeni-
tors due to overall increased need for EPC. Accordingly, an
intervention strategy may be reduction in inflammatory
states: this may be performed in a potent means by
administration of agents such as TNF blockers [55], or
more chronically by dietary supplements [117,118],
caloric restriction [119], exercise [120,121], consuming
blueberries [122], green tea [123], or statin therapy [124].
One example of a large scale intervention was the JUPITER
trial of >17,000 healthy persons without hyperlipidemia
but with elevated high-sensitivity C-reactive protein lev-
els, Crestor significantly reduced the incidence of major
cardiovascular incidents as well as lowering CRP levels
[124]. Crestor has been shown to increase circulating EPC
levels in vivo [125], in part through reduction of detri-
mental effects of asymmetric dimethylarginine on EPC
[126].
Besides attempting to reduce inflammation, administra-
tion of EPC is another therapeutic possibility. The area of
cardiac regeneration has been subject to most stem cell
investigation besides hematopoietic reconstitution. Spe-
cifically, several double blind studies have been per-
formed demonstrating overall increased cardiac function
and reduction in pathological remodeling subsequent to
administration of autologous bone marrow mononuclear
cells [127-129]. Original thoughts regarding the use of
bone marrow stem cells in infarcts revolved around stud-
ies showing "transdifferentiation" of various bone mar-
row derived cells into cells with myocardial features
[130,131]. While this concept is attractive, it has become
very controversial in light of several studies demonstrating
extremely minute levels of donor-derived cardiomyocytes,
despite clinical improvement [132,133]. An idea that has
attracted interest is that bone marrow cells contain high
numbers of EPC [134], so the therapeutic effect post inf-
arct may not necessarily need to be solely based on regen-
eration via transdifferentiation, but via production of new
blood vessels in the injured myocardium mediated by
administered EPC in the bone marrow [135]. This view is
supported by studies demonstrating that administration
of EPC in other conditions of injury or fibrotic healing
results in reduced tissue damage and organ functionality.
Instead of administering EPC another therapeutic possi-
bility is to "reposition" them or simply to mobilize them
from bone marrow sources. As previously discussed, myo-
cardial and cerebral infarcts seem to cause a "natural
mobilization", which may be part of the endogenous
response to injury. These observations led investigators to
assess whether agents that mobilize EPC may be used
therapeutically. Granulocyte colony stimulating factor (G-
CSF) has been used clinically for mobilization of hemat-
opoietic stem cells (HSC) for more than a decade during
donor stem cell harvesting. Mechanistically G-CSF is
believed to induce a MMP-dependent alteration of the
SDF-1 gradient in the bone marrow [136,137], as well as
function through a complement-dependent remodelingJournal of Translational Medicine 2009, 7:106 http://www.translational-medicine.com/content/7/1/106
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of the bone marrow extracellular matrix [138,139]. It was
found that in addition to mobilizing HSC, G-CSF stimu-
lates mobilization of EPC as well, through mechanisms
that are believed to be related [35,140]. Several studies
have been performed in which G-CSF was administered
subsequent to infarct. Although it is impossible to state
whether the mobilization of HSC or EPC accounted for
the beneficial effects, we will overview some of these stud-
ies.
The Front-Integrated Revascularization and Stem Cell Lib-
eration in Evolving Acute Myocardial Infarction by Gran-
ulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) trial
evaluated 30 patients with ST-elevation myocardial infarc-
tion treated with control or G-CSF after successful revascu-
larization [141]. Fifteen patients received 6 days of G-CSF
at 10 μg/kg body weight, whereas the other 15 received
standard care only. Four months after the infarct, the
group that received G-CSF possessed a thicker myocardial
wall at the area of infarct, as compared to controls. This
was sustained over a year. Statistically significant improve-
ments in ejection fraction, as well as inhibition of patho-
logical remodeling was observed in comparison to
controls. A larger subsequent study with 114 patients, 56
treated and 58 control demonstrated "no influence on inf-
arct size, left ventricular function, or coronary restenosis"
[142]. There may be a variety of reasons to explain the dis-
crepancy between the trials. One most obvious one is that
the mobilization was conducted immediately after the
heart attack, whereas it may be more beneficial to time the
mobilization with the timing of the chemotactic gradient
released by the injured myocardium. This has been used
to explain discrepancies between similar regenerative
medicine trials [143]. Supporting this possibility is a study
in which altered dosing was used for the successful
improvement in angina [144]. Furthermore, a recent
study last year demonstrated that in 41 patients with large
anterior wall AMI an improvement in LVEF and dimin-
ished pathological remodeling was observed [145]. Thus
while more studies are needed for definitive conclusions,
it appears that there is an indication that post-infarct
mobilization may have a therapeutic role. In the future,
other clinically-applicable mobilizers may be evaluated.
For example, growth hormone, which is used in "antiag-
ing medicine" has been demonstrated to improve
endothelial responsiveness in healthy volunteers [146],
and patients with congestive heart failure [147], this
appears to be mediated through mobilization of endothe-
lial progenitor cells [148,149].
Conclusions: Nutraceutical Based Mobilization 
of EPC
One area of recent interest in the biomedical field has
been functional foods and nutraceuticals. While it is
known that alteration of diet may modulate FMD
responses, to our knowledge, little work as been reported
on dietary-supplements altering levels of circulating EPC.
The nutritional supplement Stem-Kine (Aidan Products,
Chandler, AZ) contains: ellagic acid a polyphenol antioxi-
dant found in numerous vegetables and fruits; vitamin D3
which has been shown to mildly increase circulating pro-
genitor cells; beta 1,3 glucan (previous studies have
reported administration of various beta glucans to elicit
stem cell mobilization [150]), and a ferment of the bacte-
rium,  Lactobacillus fermentum.  Lactobacillus fermentum is
generally regarded as safe, and has been in the food sup-
ply for hundreds of years as a starter culture for the pro-
duction of sour dough bread and provides for its
characteristic sour flavor. Extract of green tea, extract of
goji berries, and extract of the root of astragalus were
added prior to the fermentation process. Green tea
extracts and some components of goji berries are known
to mildly stimulate progenitor cell release, and astragalo-
sides and other molecules found in the root of astragalus
are known antioxidants that can prevent cellular damage
secondary to oxidation. Fermentation is known to
increase the bioavailability of minerals, proteins, pep-
tides, antioxidants, flavanols and other organic mole-
cules. Imm-Kine, another Lactobacillus fermentum
fermented product that includes beta 1,3, glucan has been
safely distributed for 9 years without reported side effects.
We report here data from 6 healthy volunteers supple-
mented with StemKine (under an approved IRB protocol)
for a period of 14 days (two capsules, am, two capsules
Stem-Kine Supplementation Augments Circulating EPC Figure 1
Stem-Kine Supplementation Augments Circulating 
EPC. StemKine was administered at a concentration of 
2,800 mg/day to 6 healthy volunteers. Flow cytometric analy-
sis of cells double-staining for VEGFR2 and CD34 was per-
formed with samples extracted at the indicated timepoints. 
Y-axis represents percentage double positive cells from cells.Journal of Translational Medicine 2009, 7:106 http://www.translational-medicine.com/content/7/1/106
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pm, by mouth--700 mg per capsule). To our knowledge
this is the first report of a combination of naturally occur-
ring molecules from food products altering the levels of
circulating EPCs in humans.
As seen in Figure 1, an increase in cells expressing VEGFR2
and CD34 was observed, which was maintained for at
least 14 days. These data suggest the feasibility of modu-
lating circulating EPC levels using food supplements.
Future studies integrating natural products together with
regenerative medicine concepts may lead to formulation
of novel treatment protocols applicable to age-associated
degeneration.
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